Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial
COATES L. and McInnes IB., (2025), Nature Medicine
Sonelokimab, an IL-17A- and IL-17F- inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial
COATES L. and McInnes IB., (2025), Nature Medicine
Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies.
Coates LC. et al, (2025), RMD Open, 11
Effects of Acute Time-Restricted Eating on Inflammation in Individuals With Psoriasis: Protocol for a Case-Control, Prospective Study.
Romero Arocha S. et al, (2025), JMIR Res Protoc, 14
Ethnic disparities in COVID-19 mortality and cardiovascular disease in England and Wales between 2020-2022.
Pineda-Moncusí M. et al, (2025), Nat Commun, 16
High prevalence of MASLD in Psoriasis and Psoriatic Arthritis assessed with multiparametric magnetic resonance imaging
James L. et al, (2025), Rheumatology (Oxford)
Early detection to improve outcome in people with undiagnosed psoriatic arthritis: the PROMPT research programme including RCT
McHugh N. et al, (2025), Programme Grants for Applied Research, 1 - 56
Effect of a treatment strategy utilising Golimumab, Methotrexate and Corticosteroids versus Methotrexate and Corticosteroids in early, untreated Psoriatic Arthritis: results from the GOLMePsA investigator-initiated, single centre, double-blind, parallel-group, randomised controlled trial
COATES L. et al, (2025), The Lancet Rheumatology
Psoriatic arthritis flare incidence, definition and risk factors: a systematic review.
Hojeij B. et al, (2025), Rheumatology (Oxford)
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review
COATES L. et al, (2025), Advances in Therapy
Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 42
Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL17 treatment: a clinical case
James L. et al, (2025), Rheumatology
Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL17 treatment: a clinical case
James L. et al, (2025), Rheumatology
Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Study Nested Within an English and Welsh Audit Dataset
Charlton RA. et al, (2025), Annals of the Rheumatic Diseases
The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit.
Jethwa H. et al, (2025), Rheumatology (Oxford)
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 45 - 46
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 47 - 48
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)
Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 43 - 44